Menu

Ovarian cancer forces into new tissues

Ovarian tumor cells use cellular movement proteins to penetrate protective cell layers surrounding new target tissues during metastasis.

Jun 14, 2011
Jessica P. Johnson

Ovarian cancer cells (left) push their way through a layer of mesothelial cells, leaving a hole (right)MARCIN IWANICKI AND RACHEL DAVIDOWITZ HARVARD MEDICAL SCHOOL

When an ovarian tumor begins to spread, its first targets are the other organs within the abdominal cavity, which are protected by a layer of epithelial cells known as the mesothelium.  Now, scientists have discovered how ovarian cancer cells breach that barrier to create new tumors -- brute force.  According to a study published online today (June 14) in Cancer Discovery, ovarian cancers use proteins involved in cellular movement to muscle their way past the cellular barrier.

“You can use the analogy of a snowplow,” said Ernst Lengyel, associate professor of gynecologic oncology at the University of Chicago, who was not involved in the research.  In essence, he said, the tumor cells shovel healthy mesothelial cells out of their way to get to underlying organs.

In the early stages of metastasis, tumor cell clusters called spheroids break off from the ovary and float through the abdominal cavity until they encounter the abdominal cavity walls or nearby organs such as the stomach, liver, and intestines.  But until now, scientists did not know how the tumor cells penetrated the mesothelium that surrounds these organs to form the secondary tumors characteristic of metastasis.

To determine the method of invasion, cell biologist Marcin Iwanicki of Harvard Medical School and his colleagues observed the movement of cultured mesothelial cells after addition of a tumor spheroid.  Time-lapse microscope images showed that as the tumor cells attached to the surface of the mesothelial cell layer and began to multiply, they forced the mesothelial cells to the side.  Further experiments showed that the connections between the mesothelial cells were weakened and the cells began actively migrating away from the tumor cells.

To determine how the cancer was driving this process, the researchers inhibited expression of various tumor cell proteins and watched for any effects on tumor penetration.  Three proteins -- myosin II, talin I, and an integrin protein -- were all required in order for the tumor cells to pass through the mesothelium.  The precise mechanism of cell layer penetration remains unclear, said Joan Brugge, chair of the Department of Cell Biology at Harvard Medical School and principal investigator on the study, but based on the known cellular function of these proteins, the researchers hypothesized that the 3-protein complex works by gripping the extracellular matrix and pushing the tumor cells between mesothelial cells, physically driving the cancer into the new organ.

“I think it’s an elegant study,” said Lengyel, who co-authored a Cancer Discovery editorial on the study.  “They explain the first step of ovarian cancer metastasis.”

The next challenge is to confirm the results in vivo, said Brugge.  “We’re starting to interact with some clinicians to understand whether there’s a correlation between the in vitro assay and the properties of the tumors in the gut,” she said.  If there is, Brugge said, the results may one day lead to therapies that prevent the spread of tumors throughout the abdominal cavity.

M.P. Iwanicki, et. al.  "Ovarian cancer spheroids use myosin-generated force to clear the mesothelium," Cancer Discovery, doi: 10.1158/2159-8274.CD-11-0010, 2011.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.